Complex correction of congestive heart failure syndrome in dogs with mitral valve endocardiosis

DOI: 10.26155/vet.zoo.bio.202010001
UDC 619: 616-073.97: 636.7

Authors

S. V. Pozyabin
Doctor of Veterinary Sciences, Professor, Rector of the Moscow State Academy of Veterinary Medicine and Biotechnology – MVA by K. I. Skryabin, Moscow, Russian Federation
A. A. Rudenko
Doctor of Veterinary Sciences, Professor of the Department of Veterinary Medicine of the Moscow State University of Food Production, Moscow, Russian Federation
P. A. Rudenko
Doctor of Veterinary Sciences, Professor of the Department of Veterinary Surgery, Moscow State Academy of Veterinary Medicine and Biotechnology – MVA by K. I. Skryabin, Moscow, Russian Federation

Abstract

The aim of this study was to develop and evaluate the effectiveness of complex correction of congestive cardiac decompensation syndrome in patients with mitral valve endocardiosis in dogs. In dynamics, clinical signs, biochemical, morphological parameters of blood, echocardiographic and electrocardiographic parameters were assessed in 12 dogs with mitral valve endocardiosis. It has been established that the combined use of pimobendan, telmisartan, furosemide and spironolactone as a therapy for dogs with mitral valve endocardiosis complicated by congestive heart failure can not only reduce the symptoms of chronic cardiovascular failure, but also significantly increase the duration and improve the quality of life.

Keywords

dog, endocardiosis, mitral valve, heart failure, therapy, pimobendan, telmisartan, furosemide, veroshpiron.